Details About Generic Salt ::  Anagreli

Main Medicine Class::    

(an-AGG-reh-lide)

Agrylin

Capsules

0.5 mg and 1 mg

Class: Antiplatelet agent

 Indications Thrombocythemia caused by myeloproliferative disorders to reduce platelet count and risk of thrombotic events and to relieve associated symptoms.

 Contraindications Standard considerations.

 Route/Dosage

Thrombocythemia

ADULTS: PO Initial dose: 0.5 mg 4 qid or 1 mg bid for ³ 7 days. Titrate to minimum effective dose required to maintain platelet count < 600,000 cells/mm³, or within normal range. Avoid dosage increases > 0.5 mg/day in any 1-wk period. The max recommended dose is 10 mg/day or 2.5 mg/dose.

Interactions

Sucralfate

May reduce the oral absorption of anagrelide.

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Dose-related orthostatic hypotension; edema; palpitations; chest pain; tachycardia. CNS: Headache; asthenia; dizziness; malaise; paresthesia. DERMATOLOGIC: Rash; urticaria; pruritus. GI: Low potential for nausea and vomiting; diarrhea; abdominal pain; flatulence; anorexia; dyspepsia. HEMATOLOGIC: Anemia or thrombocytopenia. HEPATIC: Dosage reduction may be required; although no specific guidelines are available. RESPIRATORY: Dyspnea; pharyngitis; cough. OTHER: Fever; pain; back pain.

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: The safety and efficacy of anagrelide in patients < 16 yr not established. Cardiovascular: Use with caution in known or suspected heart disease because anagrelide may have positive inotropic effects. Monitor ECG and systolic ejection fraction at baseline and periodically during treatment. Hepatic function impairment: Patients with evidence of hepatic dysfunction (bilirubin, AST, or measures of liver function > 1.5 times the upper limit of normal) receive anagrelide when the potential benefits of therapy outweigh the potential risks. Monitor patients closely for signs of hepatic toxicity. Renal function impairment: Patients with renal insufficiency (creatinine ³ 2 mg/dL) receive anagrelide when the potential benefits of therapy outweigh the potential risks. Monitor patients closely for signs of renal toxicity.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Store at controlled room temperature. Protect from light.
• May be taken PO without regard to meals.

 Assessment/Interventions

• While the platelet count is being lowered (usually during the first 2 wk of treatment), monitor blood counts (eg, hemoglobin, white blood cells), liver function (eg, AST, ALT), and renal function (eg, serum creatinine, BUN).
• Monitor platelet count at baseline and periodically during treatment; adjust dose as described above. Platelet count typically responds within 1 to 2 wk of initiation. Discontinue therapy or reduce dose if thrombocytopenia occurs (platelet count < 100,000 cells/mm³).

OVERDOSAGE: SIGNS & SYMPTOMS   Thrombocytopenia, which can potentially cause bleeding, cardiac and CNS toxicity.

 Patient/Family Education

• May cause fetal harm when administered to a pregnant woman. Instruct women of childbearing potential that they must not be pregnant and that they should use contraception while taking anagrelide.

Medicscientist Drug Facts

 

Drugs Class ::

(an-AGG-reh-lide)

Agrylin

Capsules

0.5 mg and 1 mg

Class: Antiplatelet agent

Indications for Drugs ::

 Indications Thrombocythemia caused by myeloproliferative disorders to reduce platelet count and risk of thrombotic events and to relieve associated symptoms.

Drug Dose ::

 Route/Dosage

Thrombocythemia

ADULTS: PO Initial dose: 0.5 mg 4 qid or 1 mg bid for ³ 7 days. Titrate to minimum effective dose required to maintain platelet count < 600,000 cells/mm³, or within normal range. Avoid dosage increases > 0.5 mg/day in any 1-wk period. The max recommended dose is 10 mg/day or 2.5 mg/dose.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Undetermined. Children: The safety and efficacy of anagrelide in patients < 16 yr not established. Cardiovascular: Use with caution in known or suspected heart disease because anagrelide may have positive inotropic effects. Monitor ECG and systolic ejection fraction at baseline and periodically during treatment. Hepatic function impairment: Patients with evidence of hepatic dysfunction (bilirubin, AST, or measures of liver function > 1.5 times the upper limit of normal) receive anagrelide when the potential benefits of therapy outweigh the potential risks. Monitor patients closely for signs of hepatic toxicity. Renal function impairment: Patients with renal insufficiency (creatinine ³ 2 mg/dL) receive anagrelide when the potential benefits of therapy outweigh the potential risks. Monitor patients closely for signs of renal toxicity.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Dose-related orthostatic hypotension; edema; palpitations; chest pain; tachycardia. CNS: Headache; asthenia; dizziness; malaise; paresthesia. DERMATOLOGIC: Rash; urticaria; pruritus. GI: Low potential for nausea and vomiting; diarrhea; abdominal pain; flatulence; anorexia; dyspepsia. HEMATOLOGIC: Anemia or thrombocytopenia. HEPATIC: Dosage reduction may be required; although no specific guidelines are available. RESPIRATORY: Dyspnea; pharyngitis; cough. OTHER: Fever; pain; back pain.

Drug Mode of Action ::  

(an-AGG-reh-lide)

Agrylin

Capsules

0.5 mg and 1 mg

Class: Antiplatelet agent

Drug Interactions ::

Interactions

Sucralfate

May reduce the oral absorption of anagrelide.

Drug Assesment ::

 Assessment/Interventions

• While the platelet count is being lowered (usually during the first 2 wk of treatment), monitor blood counts (eg, hemoglobin, white blood cells), liver function (eg, AST, ALT), and renal function (eg, serum creatinine, BUN).
• Monitor platelet count at baseline and periodically during treatment; adjust dose as described above. Platelet count typically responds within 1 to 2 wk of initiation. Discontinue therapy or reduce dose if thrombocytopenia occurs (platelet count < 100,000 cells/mm³).

OVERDOSAGE: SIGNS & SYMPTOMS   Thrombocytopenia, which can potentially cause bleeding, cardiac and CNS toxicity.

Drug Storage/Management ::

 Administration/Storage

• Store at controlled room temperature. Protect from light.
• May be taken PO without regard to meals.

Drug Notes ::

 Patient/Family Education

• May cause fetal harm when administered to a pregnant woman. Instruct women of childbearing potential that they must not be pregnant and that they should use contraception while taking anagrelide.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.